While, the S100A12 (HR = 0.56, 95%CI: 0.41–0.78, P = 0.0043), S100A13 (HR = 0.73, 95%CI: 0.53–1.01, P = 0.058) and S100Z (HR = 0.6, 95%CI: 0.37–0.96, P = 0.032) expression predicted better prognosis in grade II ovarian cancer patients (Table 1). This evidence concerns the gene S100Z and ovarian carcinoma.